Publications by authors named "Rogier Lange"

Claim this Profile
A
A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children.
A Laura Nijstad, Evelien de Vos-Kerkhof, Catherine F Enters-Weijnen, Marianne D van de Wetering, Wim J E Tissing, Rogier Lange

J Oncol Pharm Pract· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Esther W Bouman-Wammes, John M H de Klerk, Haiko J Bloemendal, Jocye M Van Dodewaard-de Jong, Rogier Lange

Clin Genitourin Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases" [Bone 91 (2016) 159-179].
Rogier Lange, Rob Ter Heine, Russ Ff Knapp, John M H de Klerk, Haiko J Bloemendal

Bone· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.
Rogier Lange, Rob ter Heine, Wessel N van Wieringen, Adrienne M Tromp, Mayke Paap

Cancer Biother Radiopharm· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.
Rogier Lange, Rob Ter Heine, Russ Ff Knapp, John M H de Klerk, Haiko J Bloemendal

Bone· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Rogier Lange, Floor Overbeek, John M H de Klerk, Pieternel C M Pasker-de Jong, Alexandra M van den Berk

Nuklearmedizin· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical rhenium-188-HEDP.
Rogier Lange, Rob Ter Heine, Toon van der Gronde, Suzanne Selles, John de Klerk

Eur J Pharm Sci· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approach.
Rogier Lange, Rob ter Heine, Clemens Decristoforo, Iván Peñuelas, Philip H Elsinga

Nucl Med Commun· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
Rob ter Heine, Rogier Lange, Oscar B Breukels, Haiko J Bloemendal, Rob G Rummenie

Int J Pharm· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis